Evidence map›Paper›PMID 40329729›Full record

ReviewAnti-cancer agents in medicinal chemistry2026

Unraveling the Resistance: Challenges and Advances in PARP Inhibitor Therapy for BRCA1/2 Breast Cancer.

Hongjun Tang, Jingsheng Chen, Kangwei Jiang, Jiangtao He, Fangming Tang, Dongbing Li, Yuye Wu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Anti-cancer agents in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. The Zinc Finger Ran-Binding Protein 3 (ZRANB3): An Advanced Perspective.International journal of molecular sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hongjun TangDepartment of Oncology, Central Hospital of Guangdong Nongken, Zhanjiang, 524002, Guangdong, China.ORCID 0000-0001-5491-3903
Jingsheng ChenDepartment of Oncology, Central Hospital of Guangdong Nongken, Zhanjiang, 524002, Guangdong, China.
Kangwei JiangMedical Department, Central Hospital of Guangdong Nongken, Zhanjiang, 524002, Guangdong, China.
Jiangtao HeDepartment of Oncology, Central Hospital of Guangdong Nongken, Zhanjiang, 524002, Guangdong, China.
Fangming TangDepartment of Cardiology, Central Hospital of Guangdong Nongken, Zhanjiang, 524002, Guangdong, China.
Dongbing LiMedical Department, Advanced Molecular Pathology Institute of Soochow University and SANO, Suzhou, 215128, China.ORCID 0000-0002-5227-9643
Yuye WuDepartment of Oncology, Central Hospital of Guangdong Nongken, Zhanjiang, 524002, Guangdong, China.ORCID 0009-0005-5976-0455

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is the most prevalent malignant tumor among women globally, with breast cancer susceptibility genes (BRCA1 and BRCA2, BRCA1/2) mutations significantly increasing the risk of developing aggressive forms of the disease. Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) have shown promise in treating BRCA1/2-mutated breast cancer by exploiting deficiencies in homologous recombination (HR) repair. However, the emergence of acquired resistance poses a significant challenge. Our study examines the mechanisms of PARPi resistance in BRCA1/2-mutated breast cancer, synthesizing recent clinical advancements and identifying key resistance pathways, including HR recovery, DNA replication fork stability, and epigenetic modifications. We also highlight potential strategies to overcome these challenges to PARPi resistance, such as combination therapies and novel targets. Our comprehensive analysis aims to inform future clinical practices and guide the development of more effective treatment strategies.

Indexed as

Antineoplastic AgentsBRCA1 ProteinBRCA2 ProteinBreast NeoplasmsDrug Resistance, NeoplasmPoly(ADP-ribose) Polymerase InhibitorsFemaleHumansPoly(ADP-ribose) PolymerasesAntineoplastic AgentsBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanPoly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesBRCA1BRCA2Breast cancercombination therapiesdrug resistance.PARP inhibitor

Identifiers

PMID40329729

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.